| Disease | Head and neck squamous cell carcinoma (HNSCC) |
| Stage of disease/treatment | Recurrent or metastatic |
| Prior therapy | Cisplatin-based chenotherapy. Anti-PD1 mmunotherapy |
| Type of study | Phase II, nonrandomized, non-blinded, single-arm study |
| Primary endpoint | The objective response rate, including confirmed complete response and confirmed partial response, according to RECIST version 1.1 |
| Secondary endpoints | Safety, progression-free survival, overall survival, pharmacokinetic analysis, and biomarkers (ctDNA, cl-NOTCH) |
| Investigator’s analysis | Active and should be pursued further |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.